12:00 AM
Oct 05, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Alpharadin Radium-223: Additional Phase II data

In the double-blind, European Phase II BC1-03 trial in 100 patients, a single-dose of IV Alpharadin met the composite primary endpoint of a dose-dependent response in pain relief and change in analgesic consumption during a 16-week period. At 8 weeks, 5, 25, 50 and 100 kBq/kg resulted in 40%, 63%, 56% and 71% response rates, respectively. Analgesic use increased in 33% of patients in the 2 lower dose groups vs. 10% in the...

Read the full 345 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >